Head-to-head ex vivo comparison of clinically used direct anticoagulant drugs
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F24%3A10486703" target="_blank" >RIV/00216208:11160/24:10486703 - isvavai.cz</a>
Alternative codes found
RIV/60162694:G44__/25:00563496 RIV/00216208:11150/24:10486703 RIV/00179906:_____/24:10486703
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=1u9KRHybe2" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=1u9KRHybe2</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00210-023-02891-x" target="_blank" >10.1007/s00210-023-02891-x</a>
Alternative languages
Result language
angličtina
Original language name
Head-to-head ex vivo comparison of clinically used direct anticoagulant drugs
Original language description
An imbalance in coagulation is associated with cardiovascular events. For prevention and treatment, anticoagulants, currently mainly xabans and gatrans, are used. The purpose of the present study was to provide a head-to-head comparison since there are no studies directly evaluating these novel anticoagulants. An additional aim was to find whether selected anthropological and biochemical factors can affect their anticoagulant properties as they are used in fixed doses. In this cross-sectional study, blood from 50 generally healthy donors was collected, and coagulation responses to dabigatran, argatroban, rivaroxaban, and apixaban, at a concentration of 1 mu M, were analyzed. Heparin was used as a positive control. Prothrombin time (PT) expressed as international normalized ratio (INR) and activated partial thromboplastin time (aPTT) were measured and compared. Rivaroxaban was the most active according to PT/INR while argatroban according to aPTT. The ex vivo anticoagulant effect measured by INR correlated inversely with body mass index (BMI) in all four anticoagulants tested. Shortening of aPTT was associated with higher cholesterol and triglyceride levels. No sex-related differences were observed in response to the anticoagulant treatments. As this was an ex vivo study and pharmacokinetic factors were not included, the influence of BMI is of high therapeutic importance.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
<a href="/en/project/NU21J-02-00021" target="_blank" >NU21J-02-00021: Differences in parameters of platelets aggregation and blood coagulation between healthy individuals and patients with metabolic diseases</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Naunyn-Schmiedeberg's Archives of Pharmacology
ISSN
0028-1298
e-ISSN
1432-1912
Volume of the periodical
397
Issue of the periodical within the volume
6
Country of publishing house
DE - GERMANY
Number of pages
10
Pages from-to
4461-4470
UT code for WoS article
001127348700001
EID of the result in the Scopus database
2-s2.0-85180191308